Back to top
more

Corcept Therapeutics (CORT)

(Delayed Data from NSDQ)

$71.48 USD

71.48
712,355

+0.96 (1.36%)

Updated Aug 7, 2025 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (77 out of 244)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Sanofi (SNY) Signs Deal to Co-Develop Teva's IBD Candidate

by Zacks Equity Research

Sanofi (SNY) and Teva enter into a collaboration deal to co-develop and co-commercialize the latter's inflammatory bowel disease candidate, TEV'574.

Zacks Equity Research

Kezar (KZR) Falls 10% on Strategic Update, Reduces Workforce

by Zacks Equity Research

Kezar (KZR) falls 10% on the decision to channel resources to one clinical candidate as part of its reprioritization efforts and slash the workforce by 41%.

Zacks Equity Research

Kinnate Biopharma (KNTE) Falls 40% in a Month: Here's Why

by Zacks Equity Research

Kinnate Biopharma (KNTE) plunges 40% in a month for the decision to streamline its pipeline to one clinical candidate as part of its reprioritization efforts and slash workforce by 70%.

Zacks Equity Research

Apellis' (APLS) Empaveli Injector Gets FDA Nod for PNH

by Zacks Equity Research

Apellis (APLS) receives the FDA approval for Empaveli Injector, a self-administred on-body device, to treat patients with paroxysmal nocturnal hemoglobinuria.

Zacks Equity Research

NRx Pharma (NRXP) to Initiate Clinical Study on NRX-101, Stock Up

by Zacks Equity Research

NRx Pharma (NRXP) receives FDA clearance to begin clinical development for its lead candidate, NRX-101, to treat chronic pain.

Zacks Equity Research

Lilly's (LLY) Eczema Candidate Lebrikizumab Faces FDA Rejection

by Zacks Equity Research

Lilly (LLY) gets a CRL for the eczema candidate, lebrikizumab, based on inspection findings at a third-party manufacturer.

Zacks Equity Research

Amicus (FOLD) Gets FDA Approval for Pompe Disease Drug

by Zacks Equity Research

Amicus (FOLD) receives approval for Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) from the FDA to treat the adult late-onset Pompe disease.

Zacks Equity Research

Bionomics (BNOX) Meets Goals in PTSD Study, Stock Rallies 244%

by Zacks Equity Research

Bionomics (BNOX) announces positive top-line results from its mid-stage study of BNC210 for the treatment of Post-Traumatic Stress Disorder. The stock of the company rallies 244%.

Zacks Equity Research

MediWound (MDWD) Surges 18.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

MediWound (MDWD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Crinetics (CRNX) Stock Surges 70% in a Month: Here's Why

by Zacks Equity Research

Crinetics (CRNX) surges 69.6% in a month due to encouraging results from its late-stage study, paltusotine, in patients with acromegaly who were switching from current standard-of-care treatment.

Zacks Equity Research

Viatris (VTRS) Gets FDA Nod for Pupil Dilation Reversal Agent

by Zacks Equity Research

Viatris (VTRS) and partner Ocuphire Pharma receive FDA approval for Ryzumvi to treat pharmacologically-induced mydriasis of the pupils.

Zacks Equity Research

Biohaven (BHVN) Up on Positive Data from Autoimmune Disease Drug

by Zacks Equity Research

Biohaven (BHVN) gains on preliminary data from a pre-clinical study on its pipeline candidate BHV-1300 targeting various autoimmune diseases.

Zacks Equity Research

Here's Why You May Invest in Cardiol Therapeutics (CRDL) Stock

by Zacks Equity Research

Here we discuss some reasons why investing in Cardiol Therapeutics (CRDL) stock now may turn out to be a prudent move.

Zacks Equity Research

Is it a Good Time to Invest in Aurinia Pharmaceuticals (AUPH)?

by Zacks Equity Research

Here we discuss why investing in Aurinia Pharmaceuticals (AUPH) stock now may be a prudent move.

Zacks Equity Research

Immunovant (IMVT) Soars on Upbeat Initial IMVT-1402 Study Data

by Zacks Equity Research

Immunovant (IMVT) announces encouraging initial results from its early-stage study of IMVT-1402. The stock of the company rallies 97%.

Zacks Equity Research

Soleno (SLNO) Soars as Prader-Willi Syndrome Study Meets Goal

by Zacks Equity Research

Soleno's (SLNO) shares rally as the late-stage study evaluating diazoxide choline for patients with Prader-Willi syndrome meets its primary and secondary endpoints.

Zacks Equity Research

Repligen (RGEN) to Acquire Fluid Management Company Metenova

by Zacks Equity Research

Repligen (RGEN) is set to acquire a Swedish company, Metenova, which focuses on manufacturing magnetic mixers for pharmaceutical and biotechnology applications.

Zacks Equity Research

AbbVie's (ABBV) Epcoritamab Gets Approval in Europe for DLBCL

by Zacks Equity Research

Tepkinly is AbbVie's (ABBV) second hematological cancer drug to be approved in the European Union. It is also the third blood cancer medicine in AbbVie's portfolio

Zacks Equity Research

Novo Nordisk (NVO), Valo Ink Deal to Develop Heart Disease Drugs

by Zacks Equity Research

Novo Nordisk (NVO) collaborates with Valo Health to discover and develop novel treatments for cardiometabolic diseases using Valo's proprietary drug development platform.

Zacks Equity Research

Biophytis (BPTS) Soars 73% on Partnership With Skyepharma

by Zacks Equity Research

Biophytis (BPTS) gains on signing a partnership with Skyepharma, for the production of regulatory batches of its lead candidate, Sarconeos (BIO101).

Zacks Equity Research

AstraZeneca's (AZN) Dato-DXd Meets Goal in Breast Cancer Study

by Zacks Equity Research

AstraZeneca (AZN) announces positive results from the late-stage study evaluating its antibody-drug conjugate, Dato-DXd, in pre-treated patients with HR+/HER2- metastatic breast cancer.

Zacks Equity Research

Seagen's (SGEN) Combo Drug Meets Goals in Bladder Cancer Study

by Zacks Equity Research

Seagen (SGEN) announces positive top-line results from its late-stage study of the Padcev/Keytruda combo in the treatment of adult patients with metastatic bladder cancer. The stock of the company rises 3.5%.

Zacks Equity Research

Moleculin (MBRX) Posts Update From Lung Cancer Study, Stock Up

by Zacks Equity Research

Moleculin (MBRX) completes enrollment in the phase II portion of the development program for its lead candidate, Annamycin, to treat soft tissue sarcoma lung metastases. The stock rises 10%.

Zacks Equity Research

Puma's (PBYI) Alisertib Gets FDA's Orphan Drug Tag for SCLC

by Zacks Equity Research

Puma's (PBYI) alisertib receives the Orphan Drug designation from the FDA for treating patients with small cell lung cancer.

Zacks Equity Research

Relmada (RLMD) Up on Positive Data for Anti-Depressant Candidate

by Zacks Equity Research

Relmada's (RLMD) shares rise on long-term efficiency and safety data from the phase III study of its lead candidate REL-1017 to treat patients with major depressive disorder.